Abbott Laboratories (ABT): Cost of Revenue
$19.32B
Year ended 2025-12-31
$19.74B
Trailing 12 months to 2026-03-31
+0.3%
3-year compound annual growth
+5.2%
5-year compound annual growth
| Period ended | Cost of Revenue | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $19.32B | +3.3% | 2026-02-20, From 2025-01-01 |
| 2024-12-31 | $18.71B | +4.1% | 2026-02-20, From 2024-01-01 |
| 2023-12-31 | $17.98B | -6.1% | 2026-02-20, From 2023-01-01 |
| 2022-12-31 | $19.14B | +3.3% | 2025-02-21, From 2022-01-01 |
| 2021-12-31 | $18.54B | +23.6% | 2024-02-16, From 2021-01-01 |
| 2020-12-31 | $15.00B | +13.4% | 2023-02-17, From 2020-01-01 |
| 2019-12-31 | $13.23B | +4.1% | 2022-02-18, From 2019-01-01 |
| 2018-12-31 | $12.71B | +2.4% | 2021-02-19, From 2018-01-01 |
| 2017-12-31 | $12.41B | +36.5% | 2020-02-21, From 2017-01-01 |
| 2016-12-31 | $9.09B | n/a | 2019-02-22, From 2016-01-01 |
Cost of Revenue at similar companies
| Company | Year ended | Cost of Revenue | Change YoY |
|---|---|---|---|
| Abbott Laboratories (ABT) | 2025-12-31 | $19.32B | +3.3% |
| Bristol Myers Squibb Co (BMY) | 2025-12-31 | $13.94B | -0.2% |
| AbbVie Inc. (ABBV) | 2025-12-31 | $18.20B | +7.7% |
| Pfizer Inc (PFE) | 2025-12-31 | $16.07B | -10.0% |
| Merck & Co., Inc. (MRK) | 2025-12-31 | $16.38B | +7.8% |
| Eli Lilly & Co (LLY) | 2025-12-31 | $11.05B | +31.3% |
| Johnson & Johnson (JNJ) | 2025-12-28 | $30.26B | +10.1% |
| Teva Pharmaceutical Industries Ltd (TEVA) | 2025-12-31 | $8.32B | -1.9% |
| Viatris Inc (VTRS) | 2025-12-31 | $9.29B | +1.9% |
Compare ABT, BMY, ABBV, PFE side by side · Screen every company in Pharmaceutical Preparations ↗